Roche says Herceptin with Pertuzumab "impressive"
ZURICH (Reuters) - Roche Holding AG's Herceptin combined with Pertuzumab showed "impressive results" in a Phase II breast cancer trial, the Swiss drugmaker said on Friday.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=G7GGSa" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=G7GGSa)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=AEmxaH" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=AEmxaH) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=MfpKOh" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=MfpKOh) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=SqEJ2h" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=SqEJ2h)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/301030926" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/301030926/idUSL3024974120080530